Regeneron and Sanofi Report P-III Trial (BOREAS) Results of Dupixent (dupilumab) for Chronic Obstructive Pulmonary Disease
Shots:
- The P-III trial (BOREAS) evaluating Dupixent vs PBO added to maximal SoC inhaled therapy in 939 adults aged 40-80yrs. with mod. to sev. COPD
- The trial met its 1EPs & 2EPs i.e., 30% reduction in mod. or sev. acute COPD exacerbations over 52wks., improved lung function from baseline by 160mL vs 77mL @12wks. & the benefit was sustained through 52wks. The therapy also met all EPs incl. improvement in patient-reported health-related QoL & reduction in the severity of respiratory symptoms of COPD
- The safety results were consistent with the known safety profile of Dupixent in its approved indications, and overall rates of AEs (77% vs 76%). The ongoing second, replicate P-III trial (NOTUS) results of Dupixent are expected in 2024
Ref: Regeneron | Image: Regeneron
Related Post:- Regeneron’s Dupixent (dupilumab) Receives EC’s Approval as First Targeted Medicine for Severe Atopic Dermatitis
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
